Deletion of the beta 2 nicotinic acetylcholine receptor subunit alters development of tolerance to nicotine and eliminates receptor upregulation
- First Online:
- 160 Downloads
Chronic nicotine exposure induces both tolerance and upregulation of [3H]nicotine binding sites in rodent and human brain. However, the mechanism for chronic tolerance is unclear because a direct relationship between tolerance and receptor upregulation is not consistently observed.
In the present experiments, the role of β2* nicotinic acetylcholine receptors (nAChRs) on tolerance development and nAChR upregulation was examined following chronic nicotine treatment of β2 wild-type (+/+), heterozygous (+/−), and null mutant (−/−) mice.
Saline or nicotine (1, 2, or 4 mg/kg/h) was infused intravenously for 10 days. Locomotor activity and body temperature responses were measured before and after nicotine challenge injection to observe changes in nicotine sensitivity. [3H]Epibatidine binding was then measured in ten brain regions.
β2+/+ mice developed dose-dependent tolerance and upregulation of [3H]epibatidine binding sites. In contrast, β2−/− mice, initially less sensitive to acute nicotine's effects, became more sensitive following treatment with the lowest chronic dose (1 mg/kg/h). β2−/− mice treated with 4.0 mg/kg/h nicotine were no longer supersensitive, indicating that tolerance developed at this higher dose. However, these changes in nicotine sensitivity occurred in the absence of any nAChR changes in either low- or high-affinity [3H]epibatidine sites. Responses of β2+/− mice were intermediate between wild-type and mutant mice.
Upregulation of nAChRs in vivo requires the presence of the β2 subunit. Changes in nicotine sensitivity occurred both in the presence (β2+/+) and absence (β2−/−) of β2* nAChRs and suggest that mechanisms involving both β2* and non-β2* nAChR subtypes modulate adaptation to chronic nicotine exposure.
KeywordsNicotine β2 null mutant mouse Tolerance Sensitivity Receptor upregulation [3H]Epibatidine
- Avila AM, Davila-Garcia MI, Ascarrunz VS, Xiao Y, Kellar KJ (2003) Differential regulation of nicotinic acetylcholine receptors in PC12 cells by nicotine and nerve growth factor. J Pharmacol Exp Ther 64:974–986Google Scholar
- Lukas RJ, Changeux JP, Le Novere N, Albuquerque EX, Balfour DJ, Berg DK, Bertrand D, Chiappinelli VA, Clarke PB, Collins AC, Dani JA, Grady SR, Kellar KJ, Lindstrom JM, Marks MJ, Quik M, Taylor PW, Wonnacott S (1999) International Union of Pharmacology. XX. Current status of the nomenclature for nicotinic acetylcholine receptors and their subunits. Pharmacol Rev 51:397–401PubMedGoogle Scholar
- Marks MJ, Whiteaker P, Calcaterra J, Stitzel JA, Bullock AE, Grady SR, Picciotto MR, Changeux JP, Collins AC (1999) Two pharmacologically distinct components of nicotinic receptor-mediated rubidium efflux in mouse brain require the beta2 subunit. J Pharmacol Exp Ther 289:1090–1103PubMedGoogle Scholar
- Tritto T, McCallum SE, Waddle SA, Hutton SH, Paylor R, Collins AC, Marks MJ (2004) Null mutant analysis of responses to nicotine: deletion of beta2 nAChR subunit but not alpha7 subunit reduces sensitivity to nicotine-induced locomotor depression and hypothermia. Nicotine Tob Res 6:145–157CrossRefPubMedGoogle Scholar